Biomarker-guided stratification of autoimmune patients for biologic therapy

被引:4
|
作者
Ivison, Sabine [1 ,2 ]
Des Rosiers, Christine [3 ,4 ]
Lesage, Sylvie [3 ,5 ]
Rioux, John D. [3 ,4 ]
Levings, Megan K. [1 ,2 ]
机构
[1] Univ British Columbia, Dept Surg, Vancouver, BC, Canada
[2] BC Childrens Hosp, Res Inst, Vancouver, BC, Canada
[3] Univ Montreal, Montreal, PQ, Canada
[4] Inst Cardiol Montreal, Montreal, PQ, Canada
[5] Hop Maison Neuve Rosemont, Montreal, PQ, Canada
基金
加拿大健康研究院;
关键词
HUMAN IMMUNE-SYSTEM; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; PREDICTS RESPONSE; PERIPHERAL-BLOOD; ULCERATIVE-COLITIS; WHOLE-BLOOD; DISEASE; STIMULATION; TOCILIZUMAB;
D O I
10.1016/j.coi.2017.09.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Autoimmunity results from an intersection of genetic and environmental factors that cause patient-specific perturbations in immune homeostasis. Defining autoimmunity-associated genetic factors has led to mechanistic insight into underlying etiologies, and the development of many biologic therapies that target the immune system. However, biomarker-informed pairing of patients with optimal biologic therapy is lacking. Here, we discuss platforms commonly used to find biomarkers that predict response to biologic therapy in autoimmunity and highlight recent biomarker discoveries. We also outline how the lack of assay standardization is a barrier to successful biomarker validation. Finally, we argue that the successful development of companion biomarkers for biologic therapy requires collaborative approaches that integrate multiple platforms and enable comprehensive measurement of multiple immune pathways.
引用
收藏
页码:56 / 63
页数:8
相关论文
共 50 条
  • [41] Evaluating statistical characteristics of biomarker-guided trial designs
    Antoniou, Miranta
    Jorgensen, Andrea
    Kolamunnage-Dona, Ruwanthi
    TRIALS, 2015, 16
  • [42] Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis
    Deniau, Benjamin
    Takagi, Koji
    Asakage, Ayu
    Mebazaa, Alexandre
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (02) : 95 - 102
  • [43] Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
    Yang, Haitang
    Xu, Duo
    Schmid, Ralph A.
    Peng, Ren-Wang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [44] Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis
    Barbir, Elena-Bianca
    Mohan, Arjunmohan
    Koirala, Priscilla
    Gutierrez, Luis E.
    Giesen, Callen D.
    Lieske, John C.
    Herrmann, Sandra M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2025, 40 (03) : 602 - 604
  • [45] Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes
    Philipp Schuetz
    Beat Mueller
    Intensive Care Medicine, 2014, 40 : 141 - 141
  • [46] Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes
    Schuetz, Philipp
    Mueller, Beat
    INTENSIVE CARE MEDICINE, 2014, 40 (01) : 141 - 141
  • [47] Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials
    Felker, G. Michael
    Hasselblad, Vic
    Hernandez, Adrian F.
    O'Connor, Christopher M.
    AMERICAN HEART JOURNAL, 2009, 158 (03) : 422 - 430
  • [48] Biomarker-guided neuromodulation aids memory in traumatic brain injury
    Kahana, Michael J.
    Ezzyat, Youssef
    Wanda, Paul A.
    Solomon, Ethan A.
    Adamovich-Zeitlin, Richard
    Lega, Bradley C.
    Jobst, Barbara C.
    Gross, Robert E.
    Ding, Kan
    Diaz-Arrastia, Ramon R.
    BRAIN STIMULATION, 2023, 16 (04) : 1086 - 1093
  • [49] Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
    Liu, Hua
    Talalay, Paul
    Fahey, Jed W.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2016, 15 (05) : 602 - 613
  • [50] Biomarker-guided antibiotic cessation in sepsis: evidence and future challenges
    Claxton, Andrew N.
    Dark, Paul M.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2018, 79 (03) : 136 - 141